3 FDA Dates Biotech Investors Should Circle in 2021
Looking for stocks that could make big moves in the new year? There are at least three in the biotech space with enormous catalysts on the way that could drive their prices higher or lower overnight.
It's important for biotech investors to think long term, but a decision from the Food and Drug Administration to approve a new drug can lead to swift gains. The FDA is expected to issue approval decisions for these three drugs before the first quarter of 2021 ends.
PDUFA: Prescription drug user fee act. Data source: Company press releases.
Source Fool.com